ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/07/26	$0.000001	-99.00%	1,750
06/07/26	$0.000100	0.00%	8,197
02/07/26	$0.000100	0.00%	30,000

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 22:29:46 08/07/2026 +04			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.59M 3.31M 3.06M 5.81M 391M 5.91M 39.62M 15.53M 192M 15.4M 15.06M 666M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.13M -1.05M -967K -1.84M -124M -1.87M -12.52M -4.91M -60.74M -4.86M -4.76M -210M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
12/04/23	Insider Buy: Obseva	MT
06/04/23	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
01/04/23	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
31/03/23	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/03/23	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/03/23	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
13/03/23	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/03/23	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/03/23	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/03/23	ObsEva SA Announces Executive Changes	CI
03/03/23	Top Premarket Gainers	MT

30/08/22	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/08/22	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/07/22	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/06/22	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/04/22	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
01/04/23	ObsEva Files Year End 2022 Financial Statements	GL
23/03/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/03/23	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/04/23	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/04/23	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/04/23	Bourse Zurich: ouverture en hausse avant le long week-end pascal
01/04/23	Obseva bleibt 2022 tief in den roten Zahlen
01/04/23	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.58
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
28/02/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23/02/23	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	-99.00%	0.00%	-	-	117
ARGENX SE	-0.10%	-4.21%	+63.95%	+126.34%	56.98B
WUXI APPTEC CO., LTD.	+4.91%	-0.19%	+73.70%	+92.14%	53.58B
INSMED INCORPORATED	+1.48%	+5.97%	+22.59%	+495.47%	25.63B
BIONTECH SE	-0.59%	-4.68%	-16.82%	-12.99%	23.51B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.43B
GENMAB A/S	-0.97%	+2.35%	+37.15%	-25.15%	18.12B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+203.03%	+348.11%	16.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	14.13B
EXELIXIS, INC.	+1.76%	+2.24%	+29.57%	+195.70%	14.35B
Average	-8.83%	+0.77%	+57.19%	+152.44%	24.22B
Weighted average by Cap.	+1.42%	-0.31%	+57.40%	+142.98%

	2021	2022
Net sales	-	19.64M 17.18M 15.84M 14.66M 27.82M 1.87B 28.29M 190M 74.37M 920M 73.72M 72.12M 3.19B
Net income	-58.38M -51.07M -47.09M -43.57M -82.7M -5.57B -84.09M -564M -221M -2.74B -219M -214M -9.48B	-29.88M -26.14M -24.1M -22.3M -42.33M -2.85B -43.04M -289M -113M -1.4B -112M -110M -4.85B
Net Debt	-28.08M -24.56M -22.65M -20.96M -39.77M -2.68B -40.44M -271M -106M -1.32B -105M -103M -4.56B	-5.4M -4.72M -4.35M -4.03M -7.65M -515M -7.77M -52.14M -20.44M -253M -20.26M -19.82M -876M